You are hereJanuary 5, 2018
What’s the Stem Cells Buzz this Week? - Translating Regenerative Biology, Cord Blood Transplantation, Stem Cell Product Approval, and MSC Osteogenic Stimulation!
The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!
Translating Regenerative Biology
The study of tissue regeneration in different mammalian models has provided evidence of a range of species-specific regenerative capabilities. A new review from Ashley W. Seifert and Jennifer Simkin (University of Kentucky, Kentucky, USA) highlight how an understanding of the various mechanisms at play in an injury microenvironment in various species may allow us to create advances in regenerative therapies in human patients. For what sounds like a fascinating read, head over to STEM CELLS Translational Medicine.
HLA Homozygosity in Cord Blood Transplantation
Allogeneic human induced pluripotent stem cells (iPSCs) with a homozygous human leukocyte antigen (HLA) haplotype (HLA-homo HP) have been proposed as a cheaper and easier to achieve alternative to autologous iPSCs. Researchers from the lab of Yasuo Morishima (Central Japan Cord Blood Bank) sought to assess the allogeneic immunogenicity of iPSC transplantation from HLA-homo donors via cord blood transplantation (CBT). Interestingly, their new STEM CELLS Translational Medicine article suggests that patients possessing a single common HLA haplotype have a higher chance of yielding HLA-homo iPSCs.
Regulatory Path for an Approved Stem Cell Product
Holoclar®, the first stem cell-based medicine to receive authorization for commercial use throughout the European Union, takes the form of a graft derived from healthy patient-derived limbal stem cells (LSCs) to treat eye injuries in the same patient. At this current time, no other stem cell therapy has demonstrated the quality standards and clinical success required to achieve authorization status. Now, a new article from STEM CELLS Translational Medicine from Graziella Pellegrini (University of Modena e Reggio Emilia, Italy) reviews the regulatory pathway taken by Holoclar® to reach approval.
Osteogenic Stimulation of Mesenchymal Stem Cells
Adipose-derived mesenchymal stem cells (MSCs) come in huge number but display lower osteogenic capabilities when compared to the rarer bone marrow-derived MSCs. Now, researchers from the lab of Andre van Wijnen (Mayo Clinic, Minnesota, USA) have shown that cytochalasin D (CytoD), a fungal metabolite, act as an osteogenic stimulant of MSCs by blocking both cytoplasmic actin polymerization and gene-suppressive epigenetic mechanisms required for the acquisition of the osteogenic phenotype. See STEM CELLS Translational Medicine now for what could be an essential part of bone-related regenerative strategies.
That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!